Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Leases: 2019-2024

Historic Current Leases for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $4.5 million.

  • BridgeBio Pharma's Current Leases rose 15.09% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 15.09%. This contributed to the annual value of $4.5 million for FY2024, which is 9.16% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Current Leases of $4.5 million as of FY2024, which was up 9.16% from $4.1 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Current Leases ranged from a high of $4.9 million in FY2021 and a low of $3.7 million during FY2022.
  • Moreover, its 3-year median value for Current Leases was $4.1 million (2023), whereas its average is $4.1 million.
  • Per our database at Business Quant, BridgeBio Pharma's Current Leases crashed by 52.56% in 2020 and then surged by 30.12% in 2021.
  • Over the past 5 years, BridgeBio Pharma's Current Leases (Yearly) stood at $3.8 million in 2020, then soared by 30.12% to $4.9 million in 2021, then dropped by 25.58% to $3.7 million in 2022, then increased by 12.33% to $4.1 million in 2023, then grew by 9.16% to $4.5 million in 2024.